Update from the NCI Acting Director

Douglas R. Lowy
Acting Director, National Cancer Institute
National Institutes of Health

Joint NCAB/BSA Meeting
June 20, 2017
Norman E. (Ned) Sharpless

- To be named NCI Director by the President
Warren Kibbe

- Acting Deputy Director, CBIIT Director
  - CBIIT = Center for Biomedical Informatics and Information Technology
- Moving to Duke in August
- New positions:
  - Chief for Translational Biomedical Informatics in the Department of Biostatistics and Bioinformatics, Duke University School of Medicine;
  - Chief Data Officer, Duke Cancer Institute
NCI APPROPRIATIONS 2013-2017 (in billions)

- FY 2013: $4.82 billion
- FY 2014: $4.92 billion
- FY 2015: $4.95 billion
- FY 2016: $5.22 billion
- FY 2017: $5.39 billion

+$300 million for Cancer Moonshot
Doug Lowy & Tony Fauci with Senator Roy Blunt & Congressman Tom Cole (May 2, 2017)
Importance of Research Supported by NCI’s Regular Appropriation (1)

- Largely non-overlapping with Cancer Moonshot research activities
- Some ongoing examples:
  - Training the next generation of investigators
  - Investigator-initiated research
  - Most clinical trials
  - PMI Oncology
  - RAS initiative
Importance of Research Supported by NCI’s Regular Appropriation (2)

- Some new initiatives:
  - National Cryo-Electron Microscopy Facility, FNLCR
    - FNLCR = Frederick National Laboratory for Cancer Research
    - https://www.cancer.gov/research/resources/cryoem
  - TMIST breast cancer screening trial
    - TMIST = Tomosynthesis Mammographic Imaging Screening Trial
TMIST Breast Cancer Screening Trial

- Collaboration with ECOG-ACRIN
- Primary goal: Determine if *cumulative rate of advanced breast cancer* in women undergoing screening with *tomosynthesis plus digital mammography* is reduced compared to *digital mammography alone*
- RCT, 165,000 women 45-74
- Menopausal normal risk: biennial screens: 0, 24, 48 months
- Menopausal increased risk: annual screens: 0, 12, 24, 36, 48 months
- Biorepository
One Dose HPV Vaccine Efficacy Trial: Moonshot

- Goal: Determine if a single HPV vaccine dose confer long-term protection in adolescent girls
- Four arm Non-inferiority RCT in Costa Rica: 1 & 2 doses Gardasil-9 (Merck), 1 & 2 doses Cervarix (GlaxoSmithKline)
- Primary end-point: reduction in persistent HPV16/18 cervical infection
- Collaboration between Gates Foundation and NCI; companion immunogenicity trials in USA & Tanzania; HPV serology standardization project
- Potential impact if results are positive: Increase HPV vaccine uptake, save money
- More info: Kreimer et al, JNCI 2015